Keros Therapeutics (KROS) Accounts Payables (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Accounts Payables data on file, last reported at $2.0 million in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables fell 57.26% year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2025 stood at $2.0 million (down 57.26% YoY), and the FY2025 full-year result was $2.0 million, down 57.26% from the prior year.
• Accounts Payables for Q4 2025 stood at $2.0 million, down from $2.3 million in the prior quarter.
• Across five years, Accounts Payables topped out at $7.7 million in Q2 2022 and bottomed at $1.4 million in Q2 2021.
• The 5-year median for Accounts Payables is $4.0 million (2023), against an average of $4.1 million.
• The widest annual swing landed in 2021, when Accounts Payables slumped 71.72%; it then surged 458.31% in 2022.
• A 5-year view of Accounts Payables shows it stood at $3.6 million in 2021, then fell by 8.4% to $3.3 million in 2022, then surged by 63.22% to $5.4 million in 2023, then dropped by 15.56% to $4.6 million in 2024, then tumbled by 57.26% to $2.0 million in 2025.
• The last three Accounts Payables figures came in at $2.0 million (Q4 2025), $2.3 million (Q3 2025), and $5.3 million (Q2 2025), per Business Quant data.

Peer Comparison